Last update :
20/03/2025
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
valistab
valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Epirubicin hydrochloride  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Anthracine Malaysia
Axirubicine Germany
Bendaepi Germany
Binarin Ecuador, Mexico
Crisabon Argentina
Cuatroepi Argentina
Ellence United States of America
Epidoxo Venezuela
Epifil Ecuador
Epilem Colombia, Mexico, Turkey
Epimedac Germany
Epirubicin Australia, Austria, Belgium, Denmark, Ecuador, Great Britain, Hungary, Iceland, New Zealand, Saudi Arabia, Sweden, Switzerland, Turkey, United Arab Emirates
Epirubicina Argentina, Brazil, Colombia, Ecuador, Mexico, Romania, Spain
Epirubicine Belgium, France, Switzerland
Farmarubicin Turkey
Farmorubicin Austria, Belgium, Brazil, Colombia, Denmark, Egypt, Finland, Germany, Greece, Norway, Saudi Arabia, Sweden, Switzerland
Farmorubicina Brazil, Italy, Portugal, Spain
Farmorubicine Belgium, France
Pharmorubicin Australia, Canada, Great Britain, Malaysia, New Zealand
Stability of mixtures   injection   Stability of mixtures : Epirubicin hydrochloride     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Glucose 5% 0,26 mg/ml
injection   Epirubicin hydrochloride   
injection   Palonosetron hydrochloride 26 µg/ml
23°C
4 Hour
Not specified 1955
Level of evidence A+
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iomeprol 150 mg I/ml
2-8°C
7 Day
Protect from light 3708
Level of evidence D
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iohexol 322 mg I/ml
2-8°C
7 Day
Protect from light 3708
Level of evidence D
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iopromide 310 mg I/ml
2-8°C
7 Day
Protect from light 3708
Level of evidence D
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iodixanol 325 mg I/ml
2-8°C
7 Day
Protect from light 3708
Level of evidence D
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iohexol 300 mg I/ml
2-8°C
7 Day
Protect from light 3918
Level of evidence A
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iomeprol 300 mg I/ml
2-8°C
7 Day
Protect from light 3918
Level of evidence A
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iopromide 300 mg I/ml
2-8°C
7 Day
Protect from light 3918
Level of evidence A
Polypropylene DC Beads® 25 mg/ml
injection   Epirubicin hydrochloride   
injection   Iodixanol 320 mg I/ml
2-8°C
7 Day
Protect from light 3918
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,0375 mg/ml
injection   Epirubicin hydrochloride   
injection   Etoposide 0,125 mg/ml
injection   Vindesine sulfate 0,002 mg/ml
25°C
24 Hour
Light 4352
Level of evidence A+
Polyolefine Sodium chloride 0,9% 0,0525 mg/ml
injection   Epirubicin hydrochloride   
injection   Vindesine sulfate 0,0028 mg/ml
injection   Etoposide 0,175 mg/ml
25°C
24 Hour
Light 4352
Level of evidence A+
Polyolefine Sodium chloride 0,9% 0,075 mg/ml
injection   Epirubicin hydrochloride   
injection   Etoposide 0,250 mg/ml
injection   Vindesine sulfate 0,004 mg/ml
25°C
24 Hour
Light 4352
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 1 mg/ml
injection   Epirubicin hydrochloride   
injection   Ifosfamide 50 mg/ml
4°C
28 Day
Protect from light 1317
Level of evidence D
  Mentions Légales